Holen Sie sich die Stockscreener-App
1.65
4.62%
-0.0799
Minerva Neurosciences Inc Aktie (NERV) Neueste Nachrichten
Citadel Advisors LLC Makes New Investment in Kuke Music Holding Limited (NYSE:KUKE) - Defense World
Citadel Advisors LLC Purchases New Holdings in Jiuzi Holdings, Inc. (NASDAQ:JZXN) - Defense World
Minerva Neurosciences, Inc. (NASDAQ:NERV) Shares Bought by Citadel Advisors LLC - Defense World
Minerva Neurosciences Reports Q1 2025 Earnings and Regulatory Challenges - TipRanks
Major Depressive Disorder Pipeline Appears Robust With 75+ Key Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Minerva Neurosciences, Inc. (NASDAQ:NERV) Shares Bought by Northern Trust Corp - Defense World
Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at Wall Street Zen - Defense World
Minerva Neurosciences: Q1 Earnings Snapshot - CT Insider
Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates - GlobeNewswire
NERV's Cash Reserves Decrease by $4.1 Million in Q1 2025 | NERV Stock News - GuruFocus
Minerva Neurosciences Reports First Quarter 2025 Financial Resul - GuruFocus
MINERVA NEUROSCIENCES Earnings Results: $NERV Reports Quarterly Earnings - Nasdaq
Minerva Neurosciences, Inc. SEC 10-Q Report - TradingView
Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com - Defense World
Minerva Neurosciences (NERV) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Renaissance Technologies LLC Has $285,000 Stock Holdings in Minerva Neurosciences, Inc. (NASDAQ:NERV) - Defense World
Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com - Defense World
Schizophrenia Market to Witness Significant Growth by 2034 Across 7MM as New Therapies Enter Late-Stage Trials | DelveInsight - GlobeNewswire Inc.
Schizophrenia Market to Witness Significant Growth by 2034 - GlobeNewswire
StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Minerva Neurosciences (NASDAQ:NERV) Share Price Crosses Below 200 Day Moving Average – What’s Next? - Defense World
Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com - Defense World
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV) - The AM Reporter
CLASS ACTION UPDATE for TILE, NERV and QSR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
CLASS ACTION UPDATE for BABA, NAK and NERV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
Parkinson's Disease Pipeline Analysis and Clinical Trials - openPR.com
Minerva Neurosciences stock hits 52-week low at $1.29 - Investing.com Australia
Minerva Neurosciences stock hits 52-week low at $1.29 By Investing.com - Investing.com South Africa
Major depressive disorder Drugs Market 2034: Clinical Trials, - openPR.com
Minerva Neurosciences regains Nasdaq compliance By Investing.com - Investing.com Australia
Minerva Neurosciences regains Nasdaq compliance - Investing.com India
FINAL DEADLINE ALERT: ROSEN, LEADING AND RESPECTED INVESTOR COUNSEL, Encourages Minerva Neurosciences, Inc. Investors with Large Losses to Secure Counsel Before Important February 8 Deadline – NERV - Business Wire
Parkinson's Disease Clinical Pipeline | 130+ Companies Advancing the Future of Treatment - openPR
Intra-Cellular deal, Axsome settlement drive neurological index recovery - BioWorld MedTech
Minerva Neurosciences Reports Improved 2024 Financials - TipRanks
Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.com - Defense World
0.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):